Background and objective Besides epidermal growth factor receptor (EGFR) mutation, the non-small cell lung cancer (NSCLC) of anaplastic lymphoma kinase (ALK) rearrangement becomes another important clinical subtype. A specific and high-sensitive and economical detection way is convenience for identification of ALK positive NSCLC quickly and accurately. So the objective of our research is to detect ALK rearrangement in 172 cases of NSCLC by using enhancing immunohistochemical way (ventana-IHC, V-IHC). Methods ALK rearrangement in 172 NSCLC samples was detected by using V-IHC, and positive staining cases were further verified by fluorescence in situ hybridization (FISH). Results Among 172 NSCLC cases, there were 12 positive staining. The posi...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...
INTRODUCTION Detection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non-small-cell lu...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
Background:The use of a standard immunohistochemistry (IHC) assay to detect the anaplastic lymphoma ...
IntroductionAccurate determination of ALK rearrangement is important in lung cancer patients, especi...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
BACKGROUND: Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a sub...
Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-S...
Background: Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a sub...
IntroductionPatients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (A...
Approximately 3–7 % of non-small cell lung cancers harbor an anaplastic lymphoma kinase (ALK) gene f...
Abstract Background Ventana ALK (D5F3) screening of anaplastic lymphoma kinase (ALK) gene rearrangem...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...
INTRODUCTION Detection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non-small-cell lu...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...
Patients and methods Testing for Anaplastic Lymphoma Kinas (ALK) rearrangement is now recommended fo...
Background:The use of a standard immunohistochemistry (IHC) assay to detect the anaplastic lymphoma ...
IntroductionAccurate determination of ALK rearrangement is important in lung cancer patients, especi...
Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NS...
Rearrangements of anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) define...
IntroductionALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leadin...
BACKGROUND: Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a sub...
Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-S...
Background: Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a sub...
IntroductionPatients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (A...
Approximately 3–7 % of non-small cell lung cancers harbor an anaplastic lymphoma kinase (ALK) gene f...
Abstract Background Ventana ALK (D5F3) screening of anaplastic lymphoma kinase (ALK) gene rearrangem...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...
INTRODUCTION Detection of anaplastic lymphoma kinase (ALK)-gene rearrangements in non-small-cell lu...
Patients with ALK gene rearrangements often manifest dramatic responses to crizotinib, an ALK inhibi...